Regulation & Policy Industry Analysis
Buy the information you need on Pharmaceutical Regulation & Policy. Our catalogue of reports includes specific information on Pharma Compliance, Patent Protection and Drug Registration.
RSS
previous
| China Chinese Patent Medicine Industry Report (RIC00633) 2012-2015In recent years, China's Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012... | Apr 2013 | £1,350€1,599$2,100 |
| The Path to Product Inclusion in Clinical Guidelines (FWD00095) Strategies for SuccessClinical guidelines are taking hold in the practice of medicine. Though not always voluntarily followed in real-world patient care, they increasingly form the basis of formulary and reimbursement decisions, as... | Feb 2013 | £345€409$537 |
| IVD Procedure Volume and Pricing Analysis (KAL00255) This report examines the global procedure volumes for IVD and laboratory tests. It covers only commercialized tests, specifically excluding those that are developmental or used primarily for research purposes.. Point... | Jan 2013 | £2,565€3,038$3,995 |
| China Chinese Patent Drug Processing Industry (RFC01310) 2013China chinese patent drug processing industry, 2013 is valuable for anyone who wants to invest in the chinese patent drug processing industry, to get Chinese investments; to import into China... | Jan 2013 | £2,555€3,026$3,980 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: UK (IMS00263) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Swtizerland (IMS00266) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Belgium (IMS00214) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: China (IMS00218) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: France (IMS00208) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Italy (IMS00206) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Sweden (IMS00190) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Dec 2012 | £425€503$665 |
| Publication Practices for Compliance and Credibility (FWD00090) Don't miss this up-to-the-minute report on publication practices. Pharma's efforts to disseminate the results of its clinical research have never been under such intense scrutiny. Such high levels of suspicion... | Dec 2012 | £415€492$646 |
| Market Access Taiwan (JPR00012) January 2013 will see implementation of Taiwan's "second generation" national health insurance law bringing important changes to the market for prescription medicines in one of Asia's booming tiger economies. The... | Nov 2012 | £890€1,054$1,385 |
| The World Market for Stents (KAL00117) Drug-Eluting and Bare Metal Product Markets in US, EU, Japan, India, China and ROWThe coronary stents industry is a highly competitive one in which innovation occurs rapidly and the technology landscape evolves at a fast pace. As the global population is aging and... | Oct 2012 | £2,565€3,038$3,995 |
| Advisory Committees and Speaker Bureaux (FWD00086) Ensuring CompliancePharma is faced with increasing constraints on physician participation in its advisory board and speaker bureau programs. The Physician Payment Sunshine Act, which goes into effect in the US in... | Oct 2012 | £535€634$833 |
| Pharmaceutical Pricing and Reimbursement (GBI00032) Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-MakingPharmaceutical Pricing and Reimbursement - Adoption of Health Technology Assessments (HTA) Optimizes Drug Pricing and Accelerates Reimbursement Decision-Making Summary GBI Research, leading business intelligence provider has released its latest research report, entitled... | Sep 2012 | £2,250€2,665$3,500 |
| GLOBAL PHARMA SCREEN FOR TOP PICK (MPS00024) We recommend MRK and Roche as our Top pick from Global pharma space. NVS as well is interesting, trading at defensive valuations, but except for deconsolidation, there are no major... | Jul 2012 | £320€379$500 |
| Latest Guide to Chinese Pharmaceutical GMP Regulations (ACC00019) China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB... | Jul 2012 | £480€569$750 |
| Pharmaceutical Pricing and Distribution in Japan (JPR00001) 2012 updateNo serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. Nevertheless, it remains a tough and highly competitive market to crack, with... | Jun 2012 | £890€1,054$1,385 |
| China's Guidebook for Pharmaceutical Patent Protection (ACC00008) Description China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB... | May 2012 | £960€1,137$1,495 |
| Drug Price Cuts in Top Five Countries of Europe (GBI00392) Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare CostsDrug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs Summary GBI Research, the leading business... | May 2012 | £2,250€2,665$3,500 |
| Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics (CTP00109) The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies. The report provides a detailed... | May 2012 | £1,730€2,049$2,695 |
| Regulatory Intelligence on Medical Device Recalls (GBI00386) Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for RecallRegulatory Intelligence on Medical Device Recalls - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall Summary GBI Research report, "Regulatory Intelligence on... | Apr 2012 | £2,250€2,665$3,500 |
| Pricing and Reimbursement in Generics (GBI00381) European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under PressurePricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure Summary GBI Research, the leading business intelligence provider, has released its latest research... | Apr 2012 | £2,250€2,665$3,500 |
| IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Poland (IMS00202) The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS... | Mar 2012 | £425€503$665 |
